6 Pages
English

Are Biosimilars the Road to Certain Success or High Risk Venture?

Gain access to the library to view online
Learn more

Description

Are Biosimilars the Road to CertainAre Biosimilars the Road to Certain Success or High Risk Venture? PR Newswire MOUNTAIN VIEW, California, Oct. 10, 2013 -- Discover key global trends in the ambiguous biosimilars market during Frost & Sullivan's complimentary webinar WHEN: 1:00 p.m. EDT on Thursday, Oct. 17, 2013 LOCATION: Online, with free registration Frost & Sullivan Life Sciences Senior Industry Analyst Deborah SPEAKER: Toscano The biosimilars market is on the verge of transitioning from a state of infancy to an entrenched facet of healthcare. Numerous biosimilars, or follow-on biologics, have been successfully launched in many countries outside the U.S. Lower cost biosimilar versions of more complex biologic therapies, such as monoclonal antibodies, are now eagerly awaited and expected to significantly impact healthcare costs, particularly in the US, the largest market for biotechnology. However, residual uncertainties surrounding approval and commercial uptake could considerably influence the true potential of this market. Attend this webinar to: • Discover the issues around regulatory and payer acceptance of biosimilars in the U.S. • Learn how biosimilars are forecast to penetrate various biopharmaceutical segments and therapeutic areas • Understand the potential risks and rewards of this market • Gain insight into the competitive environment and potential U.S.

Subjects

Informations

Published by
Published 10 October 2013
Reads 4
Language English
Are Biosimilars the Road to Certain Success or High Risk Venture?

PR Newswire

-- Discover key global trends in the ambiguous biosimilars market during Frost & Sullivan's complimentary webinar

WHEN:                

1:00 p.m. EDT on Thursday, Oct. 17, 2013

LOCATION:       

Online, with free registration

SPEAKER:          

Frost & Sullivan Life Sciences Senior Industry Analyst Deborah Toscano